Oramed Pharmaceuticals Statistics

Total Valuation

Oramed Pharmaceuticals has a market cap or net worth of ILS 348.36 million. The enterprise value is -174.64 million.

Market Cap	348.36M
Enterprise Value	-174.64M

Important Dates

The next estimated earnings date is Friday, March 7, 2025.

Earnings Date	Mar 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+2.51%
Shares Change (QoQ)	-1.67%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	33.66M

Valuation Ratios

The trailing PE ratio is 20.99.

PE Ratio	20.99
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	0.60
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-10.52
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	5.93

Financial Position

The company has a current ratio of 27.08, with a Debt / Equity ratio of 0.00.

Current Ratio	27.08
Quick Ratio	26.99
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	-6.33

Financial Efficiency

Return on equity (ROE) is 2.89% and return on invested capital (ROIC) is -4.29%.

Return on Equity (ROE)	2.89%
Return on Assets (ROA)	-4.12%
Return on Capital (ROIC)	-4.29%
Revenue Per Employee	n/a
Profits Per Employee	4.15M
Employee Count	4
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.50% in the last 52 weeks. The beta is 1.76, so Oramed Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.76
52-Week Price Change	+9.50%
50-Day Moving Average	874.12
200-Day Moving Average	923.55
Relative Strength Index (RSI)	49.21
Average Volume (20 Days)	20,319

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.22

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-48.56M
Pretax Income	26.61M
Net Income	16.60M
EBITDA	-47.76M
EBIT	-48.56M
Earnings Per Share (EPS)	0.41

Full Income Statement

Balance Sheet

The company has 528.97 million in cash and 1.59 million in debt, giving a net cash position of 529.78 million.

Cash & Cash Equivalents	528.97M
Total Debt	1.59M
Net Cash	529.78M
Net Cash Per Share	n/a
Equity (Book Value)	578.12M
Book Value Per Share	14.46
Working Capital	511.13M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -29.44 million and capital expenditures -37,173, giving a free cash flow of -29.47 million.

Operating Cash Flow	-29.44M
Capital Expenditures	-37,173
Free Cash Flow	-29.47M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oramed Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.51%
Shareholder Yield	-2.51%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oramed Pharmaceuticals has an Altman Z-Score of 5.51.

Altman Z-Score	5.51
Piotroski F-Score	n/a